PT96068A - Processo para a producao de proteina biologicamente activa - Google Patents

Processo para a producao de proteina biologicamente activa

Info

Publication number
PT96068A
PT96068A PT96068A PT9606890A PT96068A PT 96068 A PT96068 A PT 96068A PT 96068 A PT96068 A PT 96068A PT 9606890 A PT9606890 A PT 9606890A PT 96068 A PT96068 A PT 96068A
Authority
PT
Portugal
Prior art keywords
production
biologically active
active proteins
beta
tgf
Prior art date
Application number
PT96068A
Other languages
English (en)
Other versions
PT96068B (pt
Inventor
Nico Cerletti
Albert Schmitz
Gary Kent Mcmaster
David Cox
Bernd Meyhack
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of PT96068A publication Critical patent/PT96068A/pt
Publication of PT96068B publication Critical patent/PT96068B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT96068A 1989-12-06 1990-12-04 Processo para a producao de proteina biologicamente activa PT96068B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898927546A GB8927546D0 (en) 1989-12-06 1989-12-06 Process for the production of biologically active tgf-beta

Publications (2)

Publication Number Publication Date
PT96068A true PT96068A (pt) 1991-09-30
PT96068B PT96068B (pt) 1998-02-27

Family

ID=10667491

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96068A PT96068B (pt) 1989-12-06 1990-12-04 Processo para a producao de proteina biologicamente activa

Country Status (23)

Country Link
US (2) US5650494A (pt)
EP (2) EP0891985A1 (pt)
JP (1) JP3048061B2 (pt)
KR (1) KR100203230B1 (pt)
AT (1) ATE178616T1 (pt)
AU (1) AU638075B2 (pt)
CA (1) CA2031430C (pt)
DE (1) DE69033040T2 (pt)
DK (1) DK0433225T3 (pt)
ES (1) ES2132066T3 (pt)
FI (1) FI103278B1 (pt)
GB (1) GB8927546D0 (pt)
GR (1) GR3030703T3 (pt)
HU (1) HU218144B (pt)
IE (2) IE990992A1 (pt)
IL (1) IL96549A (pt)
MX (1) MX172600B (pt)
NO (1) NO301768B1 (pt)
NZ (1) NZ236333A (pt)
PH (1) PH31649A (pt)
PT (1) PT96068B (pt)
SG (1) SG52690A1 (pt)
ZA (1) ZA909762B (pt)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU664021B2 (en) * 1990-09-05 1995-11-02 Natinco Nv Solubilization of proteins in active forms
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
KR100259827B1 (ko) * 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
US20080070842A1 (en) * 1991-11-04 2008-03-20 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
CA2129820C (en) * 1992-02-12 2003-06-17 Helge Neidhardt Dna sequences encoding novel growth/differentiation factors
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Reaktivierung von gereinigten Membranproteinen
WO1994015968A1 (en) * 1993-01-08 1994-07-21 The Upjohn Company Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
DE69429617T2 (de) 1993-04-30 2002-08-22 Biognostik Gesellschaft Fuer Biomolekulare Diagnostik Mbh Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
CA2149657A1 (en) * 1993-09-29 1995-04-06 Billie M. York Compositions containing growth factors and antiplastic agents
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
CA2194177A1 (en) * 1994-07-25 1996-02-08 Jui Yoa Chang Process for folding of proteins like recombinant hirudin or epidermal growth factor
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
PT955313E (pt) 1995-04-19 2006-07-31 Bioph Biotech Entw Pharm Gmbh Nova proteina e processo para a sua producao
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
EP0943690B1 (en) * 1995-12-21 2006-11-29 Ajinomoto Co., Inc. Method for refolding human activin a
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US6273598B1 (en) * 1996-01-22 2001-08-14 Creative Biomolecules, Inc. Computer system and methods for producing morphogen analogs of human OP-1
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en) 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor
US6500920B1 (en) * 1997-06-19 2002-12-31 St. Louis University Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag, Winterthur Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型TGF−βスーパーファミリータンパク質
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US7087577B2 (en) 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
EP1142908A4 (en) * 1999-01-07 2002-05-22 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING ACTIVATED PROTEINS
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
EP1190364A2 (en) 1999-04-23 2002-03-27 Massachusetts Institute Of Technology System and method for polymer notation
DE19944626A1 (de) * 1999-09-17 2001-03-22 Knoell Hans Forschung Ev Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
EP1223990B1 (en) 1999-10-15 2004-07-28 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
ES2527853T3 (es) 2000-03-08 2015-01-30 Massachusetts Institute Of Technology Heparinasa III y sus usos
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) * 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
WO2002023190A2 (en) 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP3254687A1 (en) 2001-10-04 2017-12-13 Genetics Institute LLC Methods and compositions for modulating interleukin-21 receptor activity
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
JP4458850B2 (ja) * 2002-02-05 2010-04-28 ジェイモナト ソシエテ ペル アチオニ 組換え胎盤成長因子の製造方法
RU2295535C2 (ru) * 2002-02-05 2007-03-20 Джимонат С.П.А. Рекомбинантный плацентарный фактор роста и способ его получения
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
WO2004014940A2 (en) 2002-08-13 2004-02-19 Wyeth PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR ß PROTEINS
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
US7074412B2 (en) 2003-01-30 2006-07-11 The University Of Zurich Pharmaceutical composition
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
TW200518767A (en) 2003-09-12 2005-06-16 Wyeth Corp Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
EP2335650B1 (en) 2003-12-11 2012-10-03 Isto Technologies Inc. Particulate cartilage system
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
WO2006088925A2 (en) 2005-02-14 2006-08-24 Wyeth Use of il17-f in diagnosis and therapy of airway inflammation
CN101218254A (zh) 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Bmpを投与することによって毛髪の成長を刺激するための方法
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
US20070021591A1 (en) * 2005-07-25 2007-01-25 Trubion Pharmaceuticals, Inc. Compositions and methods for protein deaggregation
GB0516204D0 (en) * 2005-08-06 2005-09-14 Riotech Pharmaceuticals Ltd Methods
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
GB0604938D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
CN101506222B (zh) * 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
MX2009004974A (es) 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
EP2134297B1 (en) 2007-04-12 2017-03-08 Zimmer, Inc. Apparatus for tissue repair
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CA2699454C (en) 2007-08-27 2012-07-24 Auxagen, Inc. Methods for inhibiting tgf-.beta.
WO2010033507A1 (en) 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
US8494140B2 (en) * 2008-10-30 2013-07-23 Centurylink Intellectual Property Llc System and method for voice activated provisioning of telecommunication services
EP2350130B1 (en) 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
SG176963A1 (en) 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
KR100991203B1 (ko) * 2010-05-10 2010-11-01 심영복 골형성 단백질의 정제 방법
US20140148387A1 (en) 2010-09-01 2014-05-29 Masahiro Nagaya Freeze-dried recombinant human bone morphogenetic protein-2 preparation
WO2013118877A1 (ja) * 2012-02-10 2013-08-15 株式会社ジャパニック 非ヒト幹細胞の培養上清を原材料とする化粧品又は皮膚再生促進剤、及びタンパク質のイオン導入方法
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US10919948B2 (en) 2016-12-30 2021-02-16 Biogend Therapeutics Co., Ltd. Recombinant polypeptides, compositions, and methods thereof
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
CN115919888A (zh) * 2021-07-16 2023-04-07 圣诺生物医药技术(苏州)有限公司 一种用于治疗多种肿瘤的核酸干扰药物组合物
KR102996184B1 (ko) * 2022-11-04 2026-07-27 주식회사 대웅제약 TGF-β3 단백질의 정제방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811970B (en) * 1980-03-27 1982-11-24 Lilly Co Eli Process for producing an insulin
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GR79124B (pt) * 1982-12-22 1984-10-02 Genentech Inc
WO1984004924A1 (en) * 1983-06-03 1984-12-20 Us Commerce Purified transforming growth factor-beta derived from human platelets and placentas
DE3587022T2 (de) * 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) * 1985-02-22 1988-03-15 Monsanto Company Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
EP0208539A3 (en) * 1985-07-11 1988-08-03 Repligen Corporation Folding disulfide-cross-linkable proteins
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
EP0268561A3 (en) * 1986-11-17 1988-10-26 Sandoz Ag Production and use of a novel t-cell suppressor factor
FI100106B (fi) * 1986-12-05 1997-09-30 Novartis Ag Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
ATE156491T1 (de) * 1987-05-11 1997-08-15 Chiron Corp Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
US5162507A (en) * 1987-05-11 1992-11-10 Cetus Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
EP0293785A3 (en) * 1987-05-29 1990-05-02 Oncogen Limited Partnership Cloning and expression of simian transforming growth factor-ss1
US4985544A (en) * 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5144006A (en) * 1991-06-13 1992-09-01 The Rockefeller University Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors

Also Published As

Publication number Publication date
AU6701890A (en) 1991-06-13
IL96549A (en) 2000-10-31
US5650494A (en) 1997-07-22
FI905956L (fi) 1991-06-07
ZA909762B (en) 1991-08-28
HU218144B (hu) 2000-06-28
ES2132066T3 (es) 1999-08-16
AU638075B2 (en) 1993-06-17
CA2031430A1 (en) 1991-06-07
NO905264L (no) 1991-06-07
FI905956A0 (fi) 1990-12-03
US5922846A (en) 1999-07-13
EP0433225A1 (en) 1991-06-19
JPH03191791A (ja) 1991-08-21
KR100203230B1 (ko) 1999-06-15
EP0433225B1 (en) 1999-04-07
HUT56880A (en) 1991-10-28
FI103278B (fi) 1999-05-31
FI103278B1 (fi) 1999-05-31
IL96549A0 (en) 1991-09-16
ATE178616T1 (de) 1999-04-15
CA2031430C (en) 2003-05-27
IE990992A1 (en) 2000-12-13
NO301768B1 (no) 1997-12-08
PT96068B (pt) 1998-02-27
KR910012240A (ko) 1991-08-07
EP0891985A1 (en) 1999-01-20
NZ236333A (en) 1992-03-26
HU908084D0 (en) 1991-06-28
JP3048061B2 (ja) 2000-06-05
DK0433225T3 (da) 1999-10-25
DE69033040T2 (de) 1999-09-09
DE69033040D1 (de) 1999-05-12
GR3030703T3 (en) 1999-11-30
GB8927546D0 (en) 1990-02-07
MX172600B (es) 1994-01-03
PH31649A (en) 1999-01-12
SG52690A1 (en) 1998-09-28
IE904386A1 (en) 1991-06-19
NO905264D0 (no) 1990-12-05

Similar Documents

Publication Publication Date Title
NO905264L (no) Fremgangsmaate for fremstilling av biologisk aktivt protein
ES2063278T3 (es) Proteina morfogenetica de hueso.
FI103506B1 (fi) Menetelmä syklisten aminohappojohdannaisten valmistamiseksi ja menetelmässä käytettävä välituote
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
FI885504A0 (fi) Vaskulaera antikoagulerande proteiner, dessa koderande dna, deras framstaellningsfoerfarande och deras anvaendning.
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
ES2043609T3 (es) Composiciones de interleucina-2.
PT95212A (pt) Processo para a preparacao de uma composicao para uso topico para o tratamento da fragilidade capilar, contendo defibrotide
NO179436C (no) Fremgangsmåte for fremstilling av farmasöytiske produkter for topisk bruk
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
DE69331479D1 (de) Polyethylenglycol-Hirudin-Konjugate, deren Verfahren zur Herstellung und Verwendung für die Heilung von Thrombosen
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
PT92228A (pt) Processo para a preparacao de uma formulacao oral liquida, contendo diclofenac
DE68919282D1 (de) Verfahren zur Herstellung von Cephalosporin und Zwischenverbindungen.
PT86771A (pt) Process for preparing 4-substituted benzamide derivatives with anticonvulsant activity
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
ATE106874T1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
ATE180972T1 (de) Verwendung von n-(aminoacyl)-aminosäuren zur herstellung von dopaminergen und gonadotropen arzneimitteln.
DE69010784D1 (de) Diallyloxyessigsäure und ihre basische Additionssalze, ihre Herstellungsverfahren und Verwendung als Retikularmittel.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910412

FG3A Patent granted, date of granting

Effective date: 19971118

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120518

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20121119